hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) China Challenges GLP-1 Leaders ㅤ

hengrui glp-1

hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) China Challenges GLP-1 Leaders ㅤ

Name: hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) China Challenges GLP-1 Leaders ㅤ
Brand: wefit.es
SKU: 75352340566
Price: 20.56 USD
Availability: InStock
Rating: 4.1575 (18 reviews)

SKU: 75352340566

4.2

USD20.56 USD70.56

Pay in 4 interest-free payments of $5.14 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 19 - Aug 24

Description

and identifying ferroptosis-related genes (ACSL4 and PDIA4) as prognostic biomarkers

Business Description Product Portfolio Strategic Alliances or Partnerships Recent Developments Financial Details Others Others Disclaimer MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts